RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
Thanks to @NatRevClinOncol for sharing our work on #CART cells, #cancer, and neurotoxicity. Pre-published in @BloodJournal. @MGHNeuroOnc @MGHNeurology @MGHCancerCenter
RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
RT @NatRevClinOncol: Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity af…
Also take a look at the #GIF I made explaining the recent finding on #dasatinib to manage CRS, published in @BloodAdvances https://t.co/NVukgVqFC3
Cancer #PrecisionMedicine: CAR T cell hype: yes....but be aware of the neurotoxicity
Case series from the MGH provides insights into the clinical presentation, management & biomarkers of neurotoxicity after CAR T cell therapy: https://t.co/5RBjt1hDE6. Recommendations for the management CAR T cell toxicities: https://t.co/mT1t6RRmQa &a
RT @leejanhau: A nice reference if you need one https://t.co/6GEnnL5deJ
A nice reference if you need one https://t.co/6GEnnL5deJ
RT @NatRevClinOncol: Haemofiltration shown to successfully eliminates severe cytokine release syndrome following CD19 CAR T cell therapy: h…
RT @NatRevClinOncol: Haemofiltration shown to successfully eliminates severe cytokine release syndrome following CD19 CAR T cell therapy: h…
RT @NatRevClinOncol: Haemofiltration shown to successfully eliminates severe cytokine release syndrome following CD19 CAR T cell therapy: h…
RT @NatRevClinOncol: Haemofiltration shown to successfully eliminates severe cytokine release syndrome following CD19 CAR T cell therapy: h…
Haemofiltration shown to successfully eliminates severe cytokine release syndrome following CD19 CAR T cell therapy: https://t.co/Jl2ziGBihe. Also see these recommendations for the management of CAR T cell toxicities: https://t.co/mT1t6RRmQa & https://
RT @NatRevClinOncol: With the EMA and UK NHS approvals of tisagenlecleucel for the treatment of paediatric B-ALL, these freely available ma…
RT @NatRevClinOncol: With the EMA and UK NHS approvals of tisagenlecleucel for the treatment of paediatric B-ALL, these freely available ma…
RT @NatRevClinOncol: With the EMA and UK NHS approvals of tisagenlecleucel for the treatment of paediatric B-ALL, these freely available ma…
RT @NatRevClinOncol: With the EMA and UK NHS approvals of tisagenlecleucel for the treatment of paediatric B-ALL, these freely available ma…
With the EMA and UK NHS approvals of tisagenlecleucel for the treatment of paediatric B-ALL, these freely available management guidelines could be an important resource: https://t.co/XQThmc0keq https://t.co/RGQwwonpX2
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @maljurf100: MD Anderson, PALISI Jointly Develop Pediatric Guidelines for CAR T-Cell Therapy. https://t.co/CI9s6dQ3or
MD Anderson, PALISI Jointly Develop Pediatric Guidelines for CAR T-Cell Therapy. https://t.co/CI9s6dQ3or
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
Guidelines for pediatric patients
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @hope4cancerkid: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/pATgkswwjc
RT @hope4cancerkid: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/pATgkswwjc
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
Incredible
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/pATgkswwjc
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
RT @WorldSIOP: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS…
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/fp1TZ3tgBS #pediatriconcology #childhoodcancerawareness #childhoodcancer #Kyoto #SIOP2018
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
興味深いけど、これは使える施設が限られるでしょ。
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
RT @NatRevClinOncol: OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therap…
OPEN ACCESS: Consensus management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy: https://t.co/XQThmc0keq #ayacsm #leusm #hemeonc #pedonc #ImmunoOnc #pedcsm https://t.co/E8D0uaoxOA
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
The New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients https://t.co/hedEZgbj7l
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
RT @AndreGoyMD: Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Q…
Very useful read on the New Car-T Cell Therapy Guidelines/Consensus statement for pediatric cancer patients. https://t.co/Qaali0geVW https://t.co/EO3KoPjCoY #ImmunoOnc #Castemc #ChildhoodCancer #ALL #CarTCellTherapy @JTCancerCenter @HackensackUMC https://
Dr. Mahedeo is an impressively caring, kind, and brilliant innovative physician and leader. I learn something new and valuable, every time I am in his presence. #endcancer
RT @DrPaulyDeSantis: Management guidelines for paediatric patients receiving CAR-T $NVS $GILD $CELG $AUTL https://t.co/EWfaPXETEG
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. https://t.co/wTzLpbwd67 #Neuralstemcells
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. #lymphoma #lymsm https://t.co/nr83QF8F50
RT @alex_akanell: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/G5tKd8szhu
RT @grand442003: Thank you @KidsAndCancer for supporting Vivian and Stage 4 Carcinoid Cancer. Plz read my miracle in my book Living With th…
Thank you @KidsAndCancer for supporting Vivian and Stage 4 Carcinoid Cancer. Plz read my miracle in my book Living With the Silent Enemy coming soon. Plz support M. D. Anderson to End Cancer. It Takes Lives to Save Lives.
RT @alex_akanell: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/G5tKd8szhu
RT @NatRevClinOncol: Now live with OPEN access: EXPERT CONSENSUS DOCUMENT on 'Management guidelines for paediatric patients receiving chime…
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
RT @gedefo_sefh: "Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy" https://t.co/QqpJi7gNjp
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/VQ7AdU8L86 https://t.co/UQfTYfjURi
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy https://t.co/G5tKd8szhu
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
RT @NatRevClinOncol: Now live with OPEN access: EXPERT CONSENSUS DOCUMENT on 'Management guidelines for paediatric patients receiving chime…
"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy" https://t.co/QqpJi7gNjp
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
RT @Aiims1742: Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for p…
RT @NatRevClinOncol: Now live with OPEN access: EXPERT CONSENSUS DOCUMENT on 'Management guidelines for paediatric patients receiving chime…
Another important review from the CARTOX program at @MDAndersonNews @LeukemiaMDA @CancerMedMDA: Management guidelines for pediatric patients receiving CAR T cell Rx Led by Katy Rezvani, Sattva Neelapu and @EJShpallMD In @NatRevClinOncol https://t.co/hCw
RT @BiotechRadar: it seems the CAR-T experts talked together again: CHOP and Seatlle Children's Hospital joined to the original list, but n…
it seems the CAR-T experts talked together again: CHOP and Seatlle Children's Hospital joined to the original list, but not Fred Hutch nor University of Chicago or UPenn https://t.co/9ix3u2HoIy
RT @NatRevClinOncol: Now live with OPEN access: EXPERT CONSENSUS DOCUMENT on 'Management guidelines for paediatric patients receiving chime…
Now live with OPEN access: EXPERT CONSENSUS DOCUMENT on 'Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy': https://t.co/XQThmc0keq #ayacsm #leusm #hemeonc #pedonc #ImmunoOnc #pedcsm https://t.co/ExsyVT13a9